Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Retained Earnings (2016 - 2025)

Fennec Pharmaceuticals' Retained Earnings history spans 15 years, with the latest figure at $1.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 100.57% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Dec 2025, up 100.57%, and an annual FY2025 reading of $1.2 million, up 100.57% over the prior year.
  • Retained Earnings for Q4 2025 was $1.2 million at Fennec Pharmaceuticals, up from -$224.6 million in the prior quarter.
  • The five-year high for Retained Earnings was $215.6 million in Q3 2023, with the low at -$224.6 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$116.1 million, with a median of -$183.2 million recorded in 2022.
  • Year-over-year, Retained Earnings skyrocketed 209.81% in 2023 and then plummeted 17773.45% in 2024.
  • Tracing FENC's Retained Earnings over 5 years: stood at -$175.1 million in 2021, then soared by 100.71% to $1.2 million in 2022, then changed by 0.0% to $1.2 million in 2023, then plummeted by 17773.45% to -$219.7 million in 2024, then skyrocketed by 100.57% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Retained Earnings are $1.2 million (Q4 2025), -$224.6 million (Q3 2025), and -$224.0 million (Q2 2025).